VKTX — Viking Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1607678 ·
Last close
$33.23
Market Cap
$3.88B
52W High
$42.79
52W Low
$27.16
ADV30
1,864,069
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -132,597,000 | -128,022,000 | 521,898,000 | 125,750,000 | — |
| Mar 2026 | 0 | — | -164,125,000 | -158,325,000 | 608,242,000 | 118,116,000 | 106,325,000 |
| Dec 2025 | 0 | — | -164,738,000 | -157,662,000 | 715,729,000 | 165,810,000 | 76,667,000 |
| Sep 2025 | 0 | — | -98,561,000 | -90,787,000 | 739,415,000 | 100,376,000 | 26,385,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-418,441,000
Investing CF
$399,257,000
Financing CF
$111,246,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.66
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,133,893,000
Inventory
—
Receivables
—
ST Investments
$375,913,000
EBIT TTM
$-560,021,000
Pretax Income TTM
$-534,796,000
Interest Exp TTM
—
Analysts
19
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -393,342,000 | -359,639,000 | 715,729,000 | 76,667,000 | — | -278,685,000 |
| Dec 2024 | 0 | -150,921,000 | -109,963,000 | 908,321,000 | 28,043,000 | — | -87,790,000 |
| Dec 2023 | 0 | -100,827,000 | -85,895,000 | 368,490,000 | 20,071,000 | — | -73,376,000 |
| Dec 2022 | 0 | -70,355,000 | -68,867,000 | 168,529,000 | 23,207,000 | — | -48,397,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.32
Max Pain — expiry 2026-08-28
max pain strike: $34.00 · spot: $34.38 · call oi: 9,477 · put oi: 2,762
Expected Move to 2026-08-28:
±$2.31
(6.73%) —
implied range
$32.06 –
$36.69
· ATM straddle on $34.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | $3.86B | $40.04 | — |
| RCUS | Arcus Biosciences, Inc. | $3.84B | $30.12 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.96B | $11.68 | — |
| LEGN | Legend Biotech Corp | $4.07B | $20.94 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $3.68B | $79.38 | — |
News headlines (Yahoo Finance, 1h cache)
2 GLP-1 Stocks That Could Double Your Money by 2031
2026-08-16 20:20 · Yahoo
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
2026-08-08 19:50 · Yahoo
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
2026-08-06 14:41 · Yahoo
Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says
2026-08-03 16:44 · Yahoo
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
2026-07-30 22:50 · Yahoo
VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’
2026-07-30 17:00 · Yahoo
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
2026-07-30 07:22 · Yahoo
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
2026-08-19 15:46 · Yahoo
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
2026-08-17 15:09 · Yahoo
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
2026-08-13 13:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.